

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that after considering the recommendation of the nomination committee of the Company, the Board has proposed to appoint Ms. Cheang Yee Wah, Eva (“**Ms. Cheang**”) as an independent non-executive Director with a term of office commencing from the conclusion of the 2023 AGM and for a term of three years, subject to the approval by the shareholders of the Company (the “**Shareholders**”) at the forthcoming annual general meeting of the Company (the “**2023 AGM**”). Subject to the approval by the Shareholders, the Company will appoint Ms. Cheang as a member of the audit committee of the Company.

Set forth below is the biographical details of Ms. Cheang:

Ms. Cheang, aged 48, is the company secretary of Founder Holdings Limited (stock code: 0418) since 2018. Ms. Cheang received a Bachelor of Business Administration from The University of Hong Kong and Master of Finance (Corporate Finance) from The Hong Kong Polytechnic University. She is a Chartered Financial Analysts Charterholder, a member of The Hong Kong Institute of Certified Public Accountants and an associate member of The Hong Kong Chartered Governance Institute. Ms Cheang has over 20 years’ experience in financial management, including 10 years of experience in accounting, finance, audit and corporate finance with an international audit firm and listed companies in Hong Kong.

* *For identification purpose only*

Upon approval of the appointment of Ms. Cheang as an independent non-executive Director by the Shareholders at the 2023 AGM, a letter of appointment will be entered into between the Company and Ms. Cheang for a period of three years commencing from the date of the 2023 AGM, which can be terminated by either party giving to the other not less than two months' prior written notice. She is subject to retirement by rotation and re-election at the annual general meeting of the Company under the Company's memorandum and articles of association. Ms. Cheang will be entitled to an annual remuneration of HK\$216,000 and bonus will not be paid. This is determined by the remuneration committee of the Company (the "**Remuneration Committee**") and the Board with reference to her duties and responsibilities within the Company and the prevailing market conditions, and will be subject to annual review by the Remuneration Committee and the Board.

As at the date of this announcement, Ms. Cheang (a) does not hold any other directorships in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas; (b) does not have any other major appointments and professional qualifications; (c) does not hold any position in the Company or any subsidiaries of the Company; (d) does not have any relationship with any Director, senior management, substantial shareholders or controlling shareholders of the Company as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"); and (e) does not have any interest in any share or underlying share of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, the Board is not aware of any matter in relation to the proposed appointment of Ms. Cheang that needs to be brought to the attention of the Shareholders nor any information which is required to be disclosed by the Company pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules.

The proposed appointment of Ms. Cheang as an independent non-executive Director will be submitted to the 2023 AGM for consideration and approval. A circular containing, among other matters, details of the proposed appointment of an independent non-executive Director, together with the notice of general meeting, will be dispatched to the Shareholders as soon as practicable.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 19 April 2023

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors; Dr. Li Xiaoyi and Mr. James Charles Gale are non-executive Directors; Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.